Construction of a biotechnology pharmaceutical park started Monday in the port city of Tianjin, north China.
With investment from a local pharmaceutical company and Sicor Incorporated of the United States, the park will develop and manufacture interferon.
Located in the Tianjin Development Zone, the park, known as Hualida Biotech Park, occupies 7.2 hectares (17.7 acres) with a building space of 30,000 square meters (7.4 acres).
The whole project will cost 250 million yuan (US$30 million) and be completed and put into operation in October next year.
(People's Daily September 17, 2002)
